Phase III trial meets primary endpoint for Allergan’s fibroid treatment
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Allergan, fibroid, phase 3, phase III, ulipristal, ulipristal acetate, uterine fibroid
Allergan (NYSE: AGN), in collaboration with Gedeon Richter, has announced positive results from a pivotal Phase III trial evaluating the …
Weekly Movers: Bind Therapeutics, Sarepta, Idexx…
May 9, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Pfizer (NYSE: PFE) and Amgen (Nasdaq: AMGN) are rumoured to be considering a bid for Medivation just as French drug …
Clovis cuts staff by 35% after FDA knock back on lung cancer drug
May 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing FDA, Q1 results, clovis, failure, job cuts, job losses, rociletinib, workforce
Clovis Oncology (NASDAQ: CLVS) is set to cut up to 35% of its workforce following the US Food and Drug …
NICE recommends Sanofi, Amgen cholesterol drugs
May 6, 2016Medical Communications, Sales and Marketing Amgen, Draft Guidance, NHS, NICE, Repatha, Sanofi, cardiovascular disease, cholesterol, final draft guidance, high cholesterol, praluent, recommendation, treatment
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending two new drugs for the …
KemPharm’s pain drug fails to get FDA committee backing for abuse-deterrent capabilities; shares plunge
May 6, 2016Medical Communications, Sales and Marketing
Shares in KemPharm (Nasdaq: KMPH) more than halved in pre-market trading after a US Food and Drug Administration advisory panel …
Focus: Medivation tug-of-war rumbles on
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war
Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …
Merck & Co Q1 sales hurt by generics, currency impact
May 6, 2016Medical Communications, Sales and Marketing Financial, Merck & Co, Q1, Revenye, earnings, results, sales
US pharma major Merck & Co (NYSE: MRK) posted a drop in first-quarter sales impacted the launch of generic competition …
Valeant announces new patient access and pricing committee; vows to correct past “mistakes”
May 6, 2016Medical Communications, Sales and Marketing Valeant, joseph papa, new committee, patient access, price gouging, pricing
Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …
Pfizer teams up with Wave Life Sciences for metabolic disease research
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, metabolic disease, nucelic acid therapies, partnership, wave life sciences
Pfizer (NYSE: PFE) has entered into a research, license and option agreement with Wave Life Sciences (NASDAQ: WVE) for the …
Amgen looking to join the fray, mulling Medivation bid – Reports
May 5, 2016Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
Valeant’s Bausch + Lomb teams up with IBM for cataract surgery app
May 5, 2016Research and Development Bausch and Lomb, Valeant, app, cataract, cataract surgery, ibm, ipad, iphone, surgeons
IBM (NYSE: IBM) and Bausch + Lomb, a wholly owned subsidiary of Valeant (NYSE: VRX), have announced a partnership that …
Sanofi sends letter to Medivation board; claims shareholders want takeover
May 5, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Medivation, Sanofi, board, brandicourt, hostile, shareholders, takeover
The CEO of Sanofi has issued a strongly worded letter to the board at Medivation, indicating that shareholders support their …
Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe
May 5, 2016Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma
The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …
One in three antibiotic prescriptions in US unnecessary, says CDC
May 5, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDC, antibiotic, prescribing, prescriptions, unnecessary
Approximately 30% of all prescriptions of antibiotics in the United States are unnecessary, according to new data published by the …
Eli Lilly’s cancer drug candidate scores FDA priority review
May 5, 2016Eli Lilly, US FDA, oncology, regulation
US drugmaker Eli Lilly (NYSE: LLY) said the US Food and Drug Administration (FDA) has granted priority review for its …
Bayer’s liver cancer drug meets primary endpoint in late stage trial
May 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial
Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
Biogen to spin off its haemophilia business
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off
Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …
Nice extends price-negotiation talks for PTC’ muscle wasting drug
May 4, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, market access, regulation
UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …
Pfizer revenue jumps 20%; ups FY16 outlook
May 4, 2016Research and Development, Sales and Marketing Pfizer, Q1, earnings, results, revenue, sales
US pharma giant Pfizer (NYSE: PFE) reported a 20% jump in first-quarter revenue boosted by performance of its new cancer …
Sun Pharma to partner with ICGEB to develop novel Dengue treatment
May 4, 2016Research and Development Dengue fever, Sun Pharma, collaboration, dengue, development, drug, icgeb, international centre for genetic engineering and biotechnology, partnership, sun pharmaceutical
Sun Pharmaceuticals (BSE: 85715) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) are set to team up to …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
